Western Washington Medical Group Partners with IKS Health to Boost Operations
IKS Health, a provider of care enablement platforms, has partnered with Western Washington Medical Group, a leading multi-specialty healthcare organization in Washington State. This collaboration is designed to help healthcare practices maintain autonomy and financial sustainability by streamlining revenue cycle…
Skincare: The Perfect Christmas Gift from Quanta System
The holiday season is the ideal time to slow down, reflect, and prioritize self-care. While celebrating with loved ones, there’s no greater gift than taking the time to invest in ourselves, nurturing our mind, body, and skin. Vacations are a…
Knipper Health to Acquire Commercial Sample Management Business from Thermo Fisher
Knipper Health, Inc., the leading provider of end-to-end pharmaceutical healthcare marketing services in the U.S. for the biopharmaceutical and medical industries, has announced the acquisition of Patheon Pharma Services’ sample and fulfillment operations from Thermo Fisher Scientific, based in Memphis,…
Mevion Gets Approval for First Compact Proton Therapy System in China
Mevion Medical Systems, a leader in compact proton therapy solutions, has announced that its MEVION S250i Proton Therapy System has received approval from the National Medical Products Administration (NMPA) of China. This approval marks a significant milestone, making Mevion the…
Varian’s RapidArc Enhances Treatment Planning and Delivery
Varian, a Siemens Healthineers company, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its RapidArc Dynamic solution. This innovative technology utilizes advanced algorithms to transform treatment planning, significantly reducing the time between consultation and treatment.…
GC Aesthetics® Launches 10-Year Clinical Evaluation of PERLE™ Breast Implants
GC Aesthetics® (GCA), a privately-held medical technology company specializing in aesthetic and reconstruction solutions, has announced the launch of an extensive, multi-center, prospective clinical study across Europe. This study aims to evaluate and confirm the safety, effectiveness, and patient satisfaction…
New Digostics Test Offers Accurate Gestational Diabetes Diagnosis, NHS Misses 50% of Cases
A new study published in Diabetic Medicine reveals that the standard NHS procedures for processing gestational diabetes blood sugar tests miss over 50% of cases. Gestational diabetes, if undiagnosed or untreated, can cause serious complications for both mother and baby,…
BiVACOR Total Artificial Heart Implanted in 5 Patients, FDA Approves EFS Expansion
BiVACOR, a clinical-stage medical device company, has announced the successful completion of the first phase of its FDA Early Feasibility Study (EFS) for the BiVACOR Total Artificial Heart (TAH). Between July and November 2024, five patients received the BiVACOR TAH…
Nearly 30 Million Americans with Chronic Conditions to Visit ER This Holiday Season
Cellular remote patient monitoring (RPM) from Smart Meter is a crucial tool for ensuring continuous, high-quality care, particularly during the busy holiday season. As the Centers for Disease Control and Prevention (CDC) reports, around 23% of patients with chronic conditions—roughly…
RECOVER Study Shows VNS Therapy Benefits for Treatment-Resistant Depression
LivaNova PLC (Nasdaq: LIVN), a leading medical technology company, has announced the publication of two pivotal articles in Brain Stimulation journal detailing data from the unipolar cohort of its RECOVER clinical study. This research evaluates the safety and efficacy of…
Hologic to Aid H5N1 Bird Flu Test Development in CDC Agreement
Hologic, Inc. (Nasdaq: HOLX) announced today that it has signed an agreement with the Centers for Disease Control and Prevention (CDC) to develop analyte specific reagents (ASRs) — key components of laboratory-developed tests — to assist in detecting H5N1 bird…
Sensorion Presents Phase 1/2 Trial Data of Audiogene Gene Therapy
Sensorion, a clinical-stage biotechnology company focused on hearing loss therapies, has announced promising safety data from its Phase 1/2 clinical trial, Audiogene, for SENS-501. This gene therapy targets congenital deafness caused by mutations in the OTOF (otoferlin) gene, which is…